PGZ Stock Overview
Provides specialty diagnostic services to consumer and practitioners in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Healius Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.81 |
| 52 Week High | AU$1.10 |
| 52 Week Low | AU$0.66 |
| Beta | 0.74 |
| 11 Month Change | -18.27% |
| 3 Month Change | -12.02% |
| 1 Year Change | 1.26% |
| 33 Year Change | -73.34% |
| 5 Year Change | -56.72% |
| Change since IPO | -67.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| PGZ | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 2.5% | 1.8% | 0.8% |
| 1Y | 1.3% | 17.4% | 9.1% |
Return vs Industry: PGZ underperformed the German Healthcare industry which returned 16.5% over the past year.
Return vs Market: PGZ underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| PGZ volatility | |
|---|---|
| PGZ Average Weekly Movement | 7.7% |
| Healthcare Industry Average Movement | 4.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PGZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PGZ's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 6,994 | Paul Anderson | www.healius.com.au |
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services.
Healius Limited Fundamentals Summary
| PGZ fundamental statistics | |
|---|---|
| Market cap | €602.71m |
| Earnings (TTM) | -€393.95m |
| Revenue (TTM) | €1.08b |
0.6x
P/S Ratio-1.5x
P/E RatioIs PGZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PGZ income statement (TTM) | |
|---|---|
| Revenue | AU$1.75b |
| Cost of Revenue | AU$1.21b |
| Gross Profit | AU$541.20m |
| Other Expenses | AU$1.18b |
| Earnings | -AU$636.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 30.99% |
| Net Profit Margin | -36.42% |
| Debt/Equity Ratio | 40.4% |
How did PGZ perform over the long term?
See historical performance and comparison